Extended indication Letermovir monotherapy for prophylactic treatment of cytomegalovirus infection reactivation in newborns, infants and toddlers, children and adolescent
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Letermovir
Domain Infectious diseases
Reason of inclusion Indication extension IND
Main indication Viral infections other
Extended indication Letermovir monotherapy for prophylactic treatment of cytomegalovirus infection reactivation in newborns, infants and toddlers, children and adolescents who are at risk of developing CMV infection following an allogeneic haematopoietic stem cell transplantation
Proprietary name Prevymis
Manufacturer MSD
Mechanism of action Virus inhibitor
Route of administration Oral
Therapeutical formulation Granulate
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date April 2024
Expected Registration April 2025
Orphan drug No
Registration phase Registration application pending
Additional remarks Verwachte registratie op basis van IHSI-inschatting.

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

References NCT03940586 (MK-8228-030)

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information